EUVIMEDDescoperă EUVIMED
Crossref

Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy

Wanting Hu iD, Haowei Tong iD, Maolin Zhu, Huna Wang, Xiaofei Huang, Shusheng Fan iD, Guangyao Guo, Mohammed Ismail, Lei Zhao iD, Xihua Li, Luyong Zhang iD, Qinwei Yu iD and 1 more

British Journal of Pharmacology · 2026-09 · 183 (18) · 5496-5515

DOI: 10.1111/bph.70518 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-06-26. Written by Wanting Hu and 12 co-authors. Institution: New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Major MEDLINE topics: Muscular Dystrophy, Duchenne, STAT1 Transcription Factor, Macrophages, Leflunomide. 93 references. Funded by: Postgraduate Research Practice Innovation Program of Jiangsu Province, National Key Research and Development Program of China, China Postdoctoral Science Foundation.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background and Purpose Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder caused by dystrophin gene mutations. This study investigated the therapeutic effects of leflunomide, a STAT1 inhibitor on dystrophic muscles. Experimental Design The characterization of M1 macrophage polarization and the level of STAT1/ p ‐STAT1 were measured in DMD patients. Lipopolysaccharide (LPS)/IFN‐γ and RO8191 were selected to stimulate STAT1 for evaluating the inhibitory effect of A771726 on M1 polarization and STAT1. Conditionally cocultured M1 RAW264.7 cells and differentiated C2C12 myoblasts were used to explore the differentiation of A771726 to myopathy in inflammatory environments. After 4‐week treatment with leflunomide, the protein levels of STAT1 and p ‐STAT1 were evaluated in mdx mice. CD86 and CD68 were selected for evaluating inflammation event. The proinflammatory cytokines were measured by RT‐PCR and ELISA. Muscle function and myofibre damage were examined by behavioural experiments and serum CK and LDH level, respectively. The muscle regeneration event was demonstrated by myosin heavy chain, myogenic differentiation (MyOD) protein levels and eMyHC immunofluorescence. Key Results STAT1 was remarkably upregulated in mdx mice and DMD patients compared with control groups. A771726 restrained LPS/IFN‐γ‐induced M1 macrophage polarization via inhibiting p ‐STAT1 and STAT1. Specific activation of STAT1 by RO8191 promoted macrophage polarize towards M1 type, which was partially counteracted by A771726. Leflunomide‐inhibited inflammation infiltration mediated by M1 macrophage and exerted promising therapeutic effect on muscle repair in mdx mice. Conclusions and Implications Leflunomide relieved M1 macrophage infiltration and improved muscle regeneration by downregulating STAT1 and p ‐STAT1. STAT1 may merge as a promising target for the therapy of DMD.

Subjects

MeSH terms (MEDLINE)

Muscular Dystrophy, DuchenneSTAT1 Transcription FactorMacrophagesLeflunomideRegenerationMuscle, SkeletalAnimalsMiceMice, Inbred mdxHumansMaleMice, Inbred C57BLRAW 264.7 Cells

Author keywords

Duchenne muscular dystrophyintramuscular inflammationleflunomidemuscle regenerationsignal transducer and activator of transcription 1

Substances

STAT1 Transcription FactorLeflunomideStat1 protein, mouseSTAT1 protein, human

Authors and institutions

  • New Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
  • Department of Neurology, Children's Hospital of Fudan University, Shanghai, China.
  • Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.
  • Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing, China.
  • Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Nanjing, China.

ORCID profiles: Wanting Hu, Haowei Tong, Shusheng Fan, Lei Zhao, Luyong Zhang, Qinwei Yu, Zhenzhou Jiang

Funding

  • Postgraduate Research Practice Innovation Program of Jiangsu Province
  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation
  • Experimental Animal Association Research Project Contract
  • National Basic Research Program of China

Cite

APA

Hu, W., Tong, H., Zhu, M., Wang, H., Huang, X., Fan, S., Guo, G., Ismail, M., Zhao, L., Li, X., Zhang, L., Yu, Q., & Jiang, Z. (2026). Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy. British Journal of Pharmacology, 183(18), 5496-5515. https://doi.org/10.1111/bph.70518

Vancouver

Hu W, Tong H, Zhu M, Wang H, Huang X, Fan S, et al. Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy. British Journal of Pharmacology. 2026;183(18):5496-5515. doi:10.1111/bph.70518

BibTeX
@article{Hu2026,
  author = {Hu, Wanting and Tong, Haowei and Zhu, Maolin and Wang, Huna and Huang, Xiaofei and Fan, Shusheng and Guo, Guangyao and Ismail, Mohammed and Zhao, Lei and Li, Xihua and Zhang, Luyong and Yu, Qinwei and Jiang, Zhenzhou},
  title = {Leflunomide‐inhibited STAT1 activity ameliorates intramuscular M1 macrophage infiltration and promotes muscle regeneration in Duchenne muscular dystrophy},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {18},
  pages = {5496--5515},
  doi = {10.1111/bph.70518}
}
Start for free →